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A Facile Method for Formulation 
of Atenolol Nanocrystal Drug with 
Enhanced Bioavailability
Luis Castañeda
Abstract
Atenolol is a commonly used antihypertensive drug of class III BCS category. 
The objective of the present study is to enhance the permeability of atenolol by 
using a suitable technique which is economical and devoid of using any organic 
solvents. The nanocrystal technology by high pressure homogenization was chosen 
for this purpose, which is less expensive and simple method. In this technique, no 
organic solvent was used. The study was further aimed to characterize prepared 
nanocrystals in solid state by Fourier-transform infrared spectroscopy (FTIR), 
powder X-ray diffraction (PXRD) patterns, particle size, zeta potential, % yield, 
and drug permeation study through isolated goat’s intestine. An in vivo study was 
carried out to determine the pharmacokinetic property in comparison to pure drug 
powder using rats as experimental animals. The formulation design was optimized 
by a 3(2) factorial design. In these designs, two factors, namely surfactant amount 
(X1) and speed of homogenizer (X2), were evaluated on three dependent variables, 
namely particle size (Y1), zeta potential (Y2), and production yield (Y3).
Keywords: atenolol, nanocrystal, factorial design, ANOVA, antihypertensive, 
pharmacokinetic
1. Introduction
A nanocrystal is a particle having one or more dimensions of the order of 
200 nm or less and considered to have novel characteristics which differentiate 
them from other materials [1]. When the size of the material is reduced to less than 
200 nanometers, the realm of quantum physics takes over and five materials begin 
to demonstrate entirely new properties. Hence, nanodesign of drugs by various 
different techniques, like melting, homogenization, and controlled precipita-
tion, is explored to produce drug nanocrystals, nanoparticles, nanosuspensions, 
etc. [2]. As decrease in size will increase the solubility of drugs, this technology 
is explored to increase oral bioavailability of sparingly water soluble drugs [3]. 
Development of soluble and/or permeable drug molecules using nanocrystal 
formulations has been proven to be successful due to their unique size range and 
higher surface: volume ratio, which results in enhanced drug dissolution, bioavail-
ability and permeability [4].
Atenolol is a selective β1 receptor antagonist, a drug belonging to the group of 
beta blockers, which is used mainly in different cardiovascular diseases [5]. It often 
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suffers from poor bioavailability after oral dosing due to stumpy permeability 
through GIT [6]. Approximately 50% of an oral dose is absorbed from the gastro-
intestinal tract, the remainder being excreted unchanged in the feces. Researchers 
have been endeavored to increase its permeability and bioavailability by different 
techniques including osmotic pump, cyclodextrin-based delivery systems, hydro-
philic matrices, transdermal delivery systems, and so on [7–12].
In the present study, we had prepared nanocrystals of atenolol to improve its 
permeability and modify its solubility, because this method is less time-consuming, 
required no organic solvents or harsh chemicals like other nanodelivery systems, has 
a high product yield, has good product stability, and is cheap. High pressure homog-
enization method was employed to prepare nanocrystals [13]. In this method, 
high pressure was applied on liquid suspension to force it through a gap or narrow 
channel inside a pipe. Here, the medium was aqueous containing a hydrophilic 
surfactant SLS to prevent agglomeration of suspended particles and thus it helped 
in stabilization. The surfactant used in the study also prevented crystal growth 
(Ostwald ripening) that could change the dissolution and bioavailability of the drug 
after storage [14].
2. Materials and methods
2.1 Materials
Atenolol was supplied as a gift sample by Haustus Biotech Pvt. Ltd., Himachal 
Pradesh, India, and sodium lauryl sulfate, manufactured by Krishna Drug and 
chemical Pvt. Ltd., Gujrat, was supplied by Mahalakshmi Chemicals Ltd., Greater 
Noida, India. Triple distilled water was used throughout the experiments. All other 
chemicals were of reagent grade and used without further purification.
2.2 Preparation of atenolol nanocrystals
Atenolol nanocrystals were prepared by high speed homogenization process 
using sodium lauryl sulfate as a surfactant [15–17]. The nanocrystals were prepared 
by adding the different compositions of the surfactant sodium lauryl sulfate and 
stabilizer (PVP K 30) as mentioned in Table 1. Atenolol (1000 mg) was dissolved in 
Formulation 
code
Drug: 
surfactant
Speed in 
rpm
Particle size 
(nm)
Zeta potential 
(mV)
Production 
yield
F1 2:1 20,000 312.7 ± 2.0 18 ± 0.2 82 ± 1.0
F2 4:1 20,000 296.7 ± 0.6 20 ± 0.4 88 ± 2.0
F3 4:3 20,000 416.2 ± 0.5 16 ± 0.1 84 ± 1.0
F4 2:1 25,000 210.4 ± 1.0 16.5 ± 0.3 72 ± 0.5
F5 4:1 25,000 125.6 ± 0.5 19 ± 0.2 90 ± 0.8
F6 4:3 25,000 552.6 ± 0.7 17 ± 0.3 88 ± 1.0
F7 2:1 15,000 652.6 ± 2.0 18 ± 0.7 64 ± 1.0
F8 4:1 15,000 620.0 ± 2.5 20 ± 0.4 66 ± 2.0
F9 4:3 15,000 590.0 ± 1.8 19 ± 0.5 64 ± 1.0
Table 1. 
Formulation composition of atenolol nanocrystal.
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80 ml of distilled water with sodium lauryl sulfate which resulted in a solution of 1 g 
concentration. The whole procedure was operated at 25 ± 2°C. The solution of drug 
and surfactant was placed under a high-speed homogenizer (T 25 digital ULTRA-
TURRAX IKAR Werke Staufen/Germany) at different speeds (15,000–25,000 rpm) 
for 70 h. The resulting solution was placed in a tray dryer at 60°C to evaporate the 
solvent. Nanocrystals were collected and evaluated as required.
2.3 Formulation of capsule dosage of atenolol nanocrystals
Atenolol nanocrystals were mixed with the same ratio of lactose powder, which 
shows no incompatibility with the drug. The mixture of 1:1 ratio of drug (atenolol 
nanocrystals) and lactose was prepared. Then, 100 mg of this mixture was filled 
into the capsules.
3. Characterization of nanocrystals
The nanocrystals of atenolol prepared by the abovementioned method was 
characterized by the following techniques.
3.1 Particle size and zeta potential analysis
Particle size of the prepared nanocrystals was determined using particle size 
analyzer (Malvern Instruments Ltd.). The prepared nanocrystals were dispersed in 
dimethyl sulfoxide and placed in cuvettes and the particle size in terms of average 
diameter (davg) was determined. Zeta potential was calculated by using Zetasizer 
ZS 90 (Malvern Instrument Ltd. India) [18].
3.2 Scanning electron microscopy
The morphology of the atenolol nanocrystals was examined by scanning elec-
tron microscopy (JSM 6390 India). The sample was mounted on to an aluminum 
stub and sputter coated for 120 s with platinum particles in an argon atmosphere. 
The coated samples were then scanned and images were analyzed at 500 or 1000 
axis [18].
3.3 Fourier-transform infrared (FTIR) analysis
FTIR analysis of pure atenolol, mixture of atenolol and SLS and obtained 
nanocrystals and lactose was performed in the range of 4000–500 cm−1 as thin KBr 
pellets using FTIR spectrophotometer (Perkin-Elmer BX II). The observed peaks 
were reported for functional groups.
3.4 X-ray diffraction study (XRD)
The crystallinities of atenolol and atenolol nanocrystals were evaluated by XRD 
measurement using an X-ray diffractometer (Bruker AXS, 08 Advance). All samples 
were measured in the 2θ angle range between 3 and 80° and 0.010 step sizes.
3.5 Percentage yield of production
For any formulation, it is always desirable to have a better production yield so 
that industrial production becomes feasible not only in terms of cost but also in 
Nanocrystalline Materials
4
terms of environmental protection. The production yield of prepared nanocrystals 
was calculated by the following Eq. (1):
  Percentage yield =  (B / A) × 100 (1)
where B is the weight percentage of the final product obtained after drying, and A is 
the initial total amount of atenolol and sodium lauryl sulfate used for the preparation.
3.6 In vitro release studies of atenolol nanocrystals
The dissolution test was performed in the USP type II apparatus. Nanocrystals 
(100 mg) were accurately weighed and put into the pretreated dialysis mem-
brane and sealed with clips. The release medium was phosphate buffer (pH 6.8) 
maintained at 37°C with agitation rate set at 50 rpm. The amount of drug was 
determined spectrophotometrically at λmax = 275 nm against suitable blank using a 
preconstructed calibration curve [19].
3.7 In vitro release studies of capsule dosage form of atenolol nanocrystals
The dissolution test was performed on the USP type I apparatus. Capsules con-
taining nanocrystals (100 mg) were accurately placed into the basket of dissolution 
test apparatus. The release medium was phosphate buffer (pH 6.8) maintained at 
37°C with agitation rate set at 50 rpm. The amount of drug released was determined 
spectrophotometrically at λmax = 275 nm.
3.8  In vitro intestinal permeability studies of pure atenolol and atenolol 
nanocrystals
The permeability studies of pure atenolol and atenolol nanocrystals were car-
ried out using Franz diffusion cell. To check the intra duodenal permeability, the 
duodenal part of the small intestine was isolated from sacrificed goat and taken 
for the in vitro diffusion study. Then this tissue was thoroughly washed with cold 
Ringer’s solution to remove the mucous and lumen contents. The sample solutions 
were injected into the lumen of the duodenum using a syringe, and the two sides of 
the intestine were tightly closed. Then the tissue was placed in a chamber of organ 
bath with continuous aeration and at a constant temperature of 37°C. The receiver 
compartment was filled with 30 mL of phosphate-buffered saline (pH 5.5). The per-
meability was tested for 60 minutes. The absorbance was measured using a UV-Vis 
spectrophotometer at a wavelength of 275 nm, keeping the respective blank. The 
percent diffusion of the drug was calculated against time and plotted on a graph.
3.9 Stability studies of prepared nanocrystals
The prepared nanocrystals were subjected to stability studies. The nanocrystals 
were placed in stability chambers for a month at different temperatures, like 4, 25, 
37, and 60°C. After 1 month, the tested nanocrystals were subjected to FTIR to find 
the spectra and compare with the standard spectra of nanocrystals.
3.10 In vivo studies
To determine the in vivo pharmacokinetic parameters for optimized nano-
crystal formulation, experimental rats were used. This investigation adhered to 
the Principles of Laboratory Animal Care. Female albino rats (0.20–0.25 Kg) were 
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divided in two groups, each containing six. They were fasted overnight and allowed 
to administer 0.5 mL aqueous dispersion of pure drug and the most successful 
formulation of nanocrystal (equivalent to 10 mg/mL atenolol) using oral feeding 
tube. Blood samples of 0.2 mL were withdrawn through the tail vein of rats after 0.5, 
1, 1.5, 2, 2.5, 4, 6, and 24 h of sample administration. The withdrawn samples were 
centrifuged at 5000 rpm for 20 min. The plasma was separated and stored at −20°C 
until drug analysis was carried out using HPLC analytical method of analysis. The 
whole process was carried out according to the reported method by Anwar et al. [20].
3.11 Statistical analysis
Independent T-test was used to analyze data of two batches obtained in various 
experiments at the 0.05 level of significance by Origin 6.0 software. The difference 
was considered significant at p ≤ 0.05.
3.12 Experimental design and statistical analysis
In this study, a 32 full factorial experimental design was introduced to optimize 
the formulation of nanoparticles. Initial studies were undertaken to decide on the 
factors and their levels in the experimental design. Based on the results obtained in 
preliminary experiments, surfactant amount and speed of homogenizer were found 
to be the major variables in determining the particle size and production yield. So, 
in this design, two factors, namely surfactant amount (X1) and speed of homog-
enizer (X2), were evaluated each at three levels and suitably coded (Table 2). The 
effect of these factors were evaluated on three dependent variables, namely particle 
size (Y1), zeta potential (Y2), and production yield (Y3). A total of 9 formulations 
were prepared with these variables.
For the studied design, the multiple linear regression analysis (MLRA) method 
was applied using Statistica 10 (StatSoft Inc., USA) software to fit the full second-
order polynomial equation with added interaction terms. Polynomial regression 
results were demonstrated for the studied responses using Eq. (2):
  Y = b1 + b2X1 + b3X2 + b4X1X2 + b5X12 + b6X22 (2)
Drug: surfactant (X1) Speed in rpm (X2)
−1 1
0 1
1 1
−1 0
0 0
1 0
−1 −1
0 −1
1 −1
−1 = 2:1 −1 = 15,000
0 = 4:1 0 = 20,000
+1 = 4:3 +1 = 25,000
Table 2. 
Design of experiment for  3 2 factorial analysis.
Nanocrystalline Materials
6
where Y is the dependent variable and b1 is the arithmetic mean response 
of the 9 trials. Coefficient b2 is the estimated coefficient for the factor X1, and 
coefficient b3 is the estimated coefficient for the factor X2. The main effects (X1 
and X2) represent the average result of changing one factor at a time from its 
low to high value. The interaction terms (X1X2) show how the response changes 
when two factors interact. The polynomial terms (X12 and X22) are included 
to investigate nonlinearity. The values of correlation coefficients were set to be 
statistically significant at 95% confidential interval [21]. To analyze the signifi-
cance level of all these data, ANOVA was used at 95% confidence interval at 0.05 
significance level.
4. Results and discussion
4.1 Characterization of drug, excipients, and their interactions by FTIR
FTIR spectroscopy was used to further characterize possible interactions 
between the drug and the excipients. The FTIR spectra of atenolol and sodium 
lauryl sulfate and also of the formulated nanocrystals and lactose were obtained 
at wavelength ranging from 4000 to 400 cm−1. The spectra obtained from FTIR 
studies confirmed that there was no major shifting, as well as no loss of functional 
peaks between the spectra of pure atenolol and atenolol nanocrystals. Comparing 
the spectra of pure atenolol and atenolol nanocrystals, no difference was shown 
in the position and trend of the absorption bands. All the distinctive groups in the 
FTIR spectra of atenolol were found in all the spectra of atenolol nanocrystals, like 
the amide group (O〓C–NH2) extruding from the benzene ring. Apart from the 
amide functional group, the presence of the conjugating C〓C bond in the benzene 
ring, the methane (CH), methylene (CH2) methyl (CH3), and OH functional group 
were distinctly observed in the IR spectra (amide:1650 cm−1; CH:2880–2900 cm−1; 
CH2: 2916–2936 cm
−1; CH3: 2850 cm
−1; conjugating C〓C: 1640–1610 cm−1; 
OH:3200–3550 cm−1), thus providing evidence for the absence of any chemical 
incompatibility between SLS and atenolol.
4.2 Particle size and zeta potential
The particle size of the atenolol nanocrystal formulations shown in Table 1 
showed a narrow size distribution from 125 to 652 nm, where the intensity of 
117.8 nm was 93% and that of 652.5 nm was only 7%. The effect of stirring speed 
had an enormous effect on particle size. Formulation prepared with 25,000 rpm 
had smaller size as compared to particle prepared with 15,000 rpm. Concentration 
of SLS also had an effect on the size distribution. Less concentration of SLS 
yielded smaller size particles. The formulated nanocrystals were positively charged 
(16–19 mV), which is desirable for good ocular interaction. Formulation F7 was not 
further considered due to its larger size (more than 650). This may be due to slow 
stirring speed.
4.3 Production yield
The date of percentage yield of the prepared nanocrystals (Table 1) showed 
that the atenolol-SLS nanocrystals (batch F5), prepared by drug:SLS ratio 4:1, had 
comparatively higher yield of production (90%). Stirring speed and concentration 
of SLS also had an effect on the production yield.
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4.4 Scanning electron microscopy
The SEM image, as shown in Figure 1, of the atenolol nanocrystals revealed that 
the particles were crystalline in shape. The average size of the atenolol nanocrystals 
was found to be less than 200 nm, which was further supported by the results of 
particle size analysis by Zetasizer.
4.5 X-ray diffraction (PXRD) studies
The powder X-ray diffractogram of pure atenolol powder from 5 to 50° 2 θ 
showed numerous distinctive peaks at 2 θ degree that indicated a high crystalline 
content. The samples were scanned for 2  θ values over a range from 5 to 50°C at a 
scan rate of 10°/min. The PXRD pattern of pure drug and atenolol nanocrystals 
were compared with regard to peak positions and relative intensities and presence 
and/or absence of peaks in certain regions. Figure 2 represents the XRD photograph 
of different nanocrystal formulation and pure atenolol powder.
4.6 Permeability study
The permeability study showed increased permeability, when the atenolol was 
converted into the nanocrystals. The diffusion study showed that the % perme-
ability of nanocrystal formulations was much higher as compared to that of the pure 
drug. The formulation F5 showed the maximum % release of 90.88%, whereas the 
pure drug showed only 31.22% release Figure 3.
4.7 In vitro dissolution studies
The dissolution rate of pure atenolol was very poor and during a 120-min 
period, 51.64% of drug was released. The reason for the poor dissolution of pure 
drug could be poor wettability and poor solubility. In vitro release studies revealed 
that there was a marked increase in the dissolution rate of atenolol, in the range 
of 78.30–98.28%, from all nanocrystal formulation compared to pure atenolol. 
The results revealed that the nanocrystals with a ratio of drug to carrier, 4:1, were 
having a higher dissolution rate in comparison to all other ratios. This could be 
attributed to the hydrophilic character of the surfactant and to the amorphous state 
of the drug. Hence, the present study showed that nanocrystal formulation can 
Figure 1. 
SEM images of atenolol nanocrystals.
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be successfully used to enhance dissolution rate of poorly soluble drugs. Figure 4 
shows drug release profile of pure drug nanocrystal formulation [F5] and capsu-
lated nanocrystals.
4.8 Stability studies
The physical appearance of the prepared nanocrystals after keeping them 1 month 
in stability chambers under various conditions was found to be white to off-white 
in color, odorless, and crystalline powder. FTIR spectroscopy was used to further 
characterize possible interactions between the drug and the excipients during the 
stability studies. There was no major change shown in the FTIR peaks. The prepared 
nanocrystal formulation was stable during the stability studies done for 1 month.
4.9 In vitro study
The results of in vivo study revealed an improvement in bioavailability of nanocrystal 
formulation; it was observed that after oral dosing of the drug and the equation 3, their 
Figure 2. 
XRD of atenolol nanocrystals F5 (A), atenolol pure drug (B), atenolol nanocrystals F4 (C), and nanocrystals 
F1 (D).
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individual kinetic curve exhibited double peaks. Thus, double peaks can be due to the 
existence of two absorption sites in the gut interrupted by a region of poor absorption 
[21]. A rapid attainment of peak plasma concentrations was observed that may be due to 
the burst release effect brought by the use of SLS for stabilization of nanocrystals. Same 
phenomenon was reported by Vergote et al. [22]. The AUC0–24 h, MRT, and Cpmax for 
test formulation were significantly higher at  p¡0.05 compared to the drug (Table 3).
4.10 Factorial analysis
Applied 32 factorial design yields coefficient for one factor and for two factors 
as well. Coefficient for more than one factor represents interaction of both factors. 
Figure 3. 
Permeability from Franz diffusion cell of atenolol pure drug and atenolol nanocrystal formulations.
Figure 4. 
In vivo dissolution cumulative of % release of atenolol pure drug, atenolol nanocrystals F5, and capsule dosage 
of nanocrystals in phosphate buffer (pH 6.8).
Nanocrystalline Materials
10
Coefficient may be positive or negative for synergistic or antagonistic effect, 
respectively. The coefficients can be directly compared to assess the impact of 
factors on responses. Obtained polynomial Eqs. (3)–(5) for dependent variables are 
as follows:
 Particles Size = 4280.7153 − 6169.2601 × x − 0.2812 × y + 4894.7164  
× x × x + 0.1959 × x × y + 4.6667  E −8 × y × y (3)
 Zeta potential = 31.4304 − 43.3651 × x − 0.0004 × y + 67.3401  
× x × x − 0.0004 × x × y + 1  E −8 × y × y (4)
 Production Yield = − 71.7445 − 370.4401 × x + 0.0192 × y + 606.0606  
× x × x − 0.0009 × x × y − 4.2667  E −7 × y × y (5)
Speed of homogenizer has a greater effect on the particle size (−0.2812), zeta 
potential (−0.0004), and production yield (0.0192), whereas amount of surfactant 
has a lesser effect on the production yield (−370.4401), zeta potential (−43.3651), 
and particle size (−669.2601).
It was clearly depicted from the magnitude of the coefficients that the amount 
of surfactant has a positive effect on all the three variables including particle size, 
zeta potential, and production yield; whereas, the magnitude of the coefficients for 
speed of homogenizer has an antagonistic effect on all the three variables.
Contour plots and surface plots as shown in Figures 5 and 6 were plot-
ted, which are very useful to study the interaction effects of the factors on the 
responses. The response surface depicts the effect of factor contributions at 
different levels on studied response. Three contour parameters were established 
for particle size. Drug entrapment and drug release percentage. The contour plots 
showed very clearly the relationship between the independent variables and the 
responses.
P value for the effect of drug surfactant ratio is statistically insignificant for 
particle size and production yield p has value greater that 0.05, but it is significant 
only for zeta potential (p = 0.009851) and particle size (p = 0.035269). Speed of 
homogenizer has an insignificant effect on zeta potential.
The goodness of fit of the R2 model was checked by the determination 
coefficient (R2). The values of the determination coefficients for particle size 
(R2 = 0.78297), zeta potential (R2 = 0.80392), and production yield (R2 = 0.8988) 
indicated that over 95% of the total variations are explained by the model. The 
values of adjusted determination coefficients (adj R2 = 0.56594 for particle size, 
0.60784 for zeta potential, and 0.79761 for production yield) are also very high 
(over 90% of the total variations), which indicates a high significance of the model.
A good way to check the model is to enter factor levels from the experimental 
design (observed response) and generate the predicted response. When we compare 
the predicted value with actual value, a discrepancy occurs which is called residual. 
Formulation Cpmax (μg/mL) Tmax (hour) AUC0–24 (mAU) MRT (hour)
Pure drug 612.15 ± 10.6 5.2 ± 1.4 26927.8 ± 4.2 46.56 ± 3.1
Nanocrystal 
formulation
957.51 ± 20.4 2.8 ± 0.5 75329.3 ± 6.3 84.64 ± 4.6
Table 3. 
Pharmacokinetic data of nanocrystal formulation and pure drug.
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Figure 5. 
3D surface plots for the different variables (in order of particle size, production yield, and zeta potential).
Figure 6. 
3D contour plots for the different variables (in order of particle size, production yield, and zeta potential).
Figure 7. 
Plots of residuals for the three different variables (in order of particle size, production yield, and zeta potential).
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For statistical purposes, it is assumed that the residuals are normally distributed 
and independent with constant variance [21]. Residual versus predicted plots were 
constructed to check the statistical assumptions. In this experiment, there is no 
definite increase in residuals with predicted levels, which support the underlying 
statistical assumptions of constant variance. Moreover, the obtained plots of residu-
als that do not exhibit any systematic structure indicate that the model fits the data 
well (Figure 7). Plots of the residuals versus other predictor variables, or potential 
predictors that exhibit systematic structure indicate that the form of the function 
can be improved in some ways.
5. Conclusions
In this study, atenolol nanocrystals had been developed successfully by high-
speed homogenization and simultaneous drying, which have shown an improved 
dissolution and permeability behavior compared to that of the pure drug. Statistical 
analysis revealed speed of homogenizer had bigger effect on the three observed 
parameters, whereas amount of surfactant had a lesser effect on them. SEM pic-
tures had shown that the size of the particles obtained after homogenization is 
below 1 μm. This implied that the size of the drug crystals in these particles was of 
nanoscale. Therefore, it can be concluded that the selected method of nanocrystal 
formation and its further optimization by factorial design was effective to increase 
the solubility, as well as permeability of atenolol.
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